BioNTech SE
As of Oct 22, 2026, BioNTech is in Stage 2, the uptrend phase, now in week 5 (since Sep 23, 2026). It closed at $89.67, 24.9% below its 52-week high and below its 200-day average, which is falling.
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is BNTX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
BNTX among Biotechnology234th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …234 | BNTX | Stage 2 · wk 5 | 42 | −8.9% |
BioNTech: quick answers
What stage is BioNTech in?
As of Oct 22, 2026, BioNTech (BNTX) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 23, 2026 and is in week 5. What the four stages mean
Is BioNTech in an uptrend?
Yes. BioNTech is in a Stage 2 uptrend. It trades 8.1% below its 200-day average, which is falling.
How far is BioNTech from its 52-week high?
BioNTech closed at $89.67 on Oct 22, 2026, 24.9% below its 52-week high of $119.34. Its 52-week low is $83.89.
How has BioNTech performed over the past year?
As of Oct 22, 2026, BioNTech is down 16.1% over the past year and down 7.3% so far in 2026.
Which sector and industry is BioNTech in?
BioNTech is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.